Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analogue designed to selectively stimulate your own pituitary gland to release growth hormone, rather than replacing it with synthetic GH. It has been most studied for its ability to reduce excess visceral (deep abdominal) fat, particularly in people with HIV-associated lipodystrophy, and is approved in some regions for that specific indication. Outside that setting, it is increasingly used in advanced metabolic and body-composition programs, under specialist supervision, to support a more favourable abdominal fat profile, metabolic health and healthy-ageing outcomes.

Tesamorelin binds to GHRH receptors in the pituitary and triggers a more physiological release of growth hormone, which in turn increases IGF-1 and downstream repair, metabolic and lipolytic (fat-mobilising) signals. Clinically, this has been shown to help reduce visceral adipose tissue, the “hard” fat that sits deep around the organs and is strongly linked with cardiometabolic risk, while having a more modest effect on subcutaneous fat. Rather than being a crash-diet drug, Tesamorelin is best thought of as a specialised metabolic lever: it makes the internal environment more supportive of visceral fat loss when paired with structured nutrition, training and lifestyle changes, especially in individuals who have stubborn central adiposity despite doing the right things.

Because it is an active hormone-axis therapy, Tesamorelin requires careful screening, baseline pathology and ongoing monitoring (IGF-1, lipids, glucose/insulin, cardiovascular risk markers and endocrinology red flags).

Tesamorelin is not an FDA‑approved medicine and is not intended to diagnose, treat, cure or prevent any disease. Always follow the advice of your prescribing practitioner.

When used exactly as directed and as part of a clinician-designed program, clients commonly use Tesamorelin to help support:

Reduction of deep abdominal (visceral) fat

Tesamorelin targets the growth hormone axis in a way that has been shown to reduce visceral abdominal fat, which is strongly linked to cardiometabolic risk, while aiming to preserve lean tissue when diet and training are in place.

Improved metabolic health profile

By helping shift fat away from the visceral compartment and supporting healthier GH/IGF-1 signalling, Tesamorelin can be part of a broader effort to improve markers such as waist circumference and metabolic risk factors, when combined with nutrition and exercise.

Body-composition support in high-risk or resistant cases

It is often reserved for people who have stubborn central fat despite lifestyle work, or those in structured cardiometabolic or HIV-associated lipodystrophy programs, to help change where fat is being stored in the body.

Recovery, repair and overall tissue support

Growth hormone and IGF-1 play roles in tissue repair; under proper supervision, Tesamorelin can support recovery from training and daily physical demands as part of a bigger plan.

Healthy-ageing and cardiometabolic resilience

For selected clients, Tesamorelin is integrated into longevity and cardiometabolic programs that focus on keeping visceral fat lower, muscle and function higher, and long-term risk better managed.

*Individual results vary. This peptide blend works best as part of a complete plan created with your healthcare provider and is not a substitute for healthy nutrition, movement, sleep or medical care.

Active Ingredients

Tesamorelin acetate – 4000 mcg/mL

Presentation

Tesamorelin 4000 mcg/mL multidose vial 

Total content: 20,000 mcg 5mL Vial

Excipients

Sterile diluent (e.g., bacteriostatic saline) and standard compounding excipients as specified by the partner pharmacy (may include buffering agents and preservatives.

Protocol & Standard Dosing

Pre-conditions (“no red flags”), Baseline pathology reviewed (including IGF-1, cholesterol profile and relevant endocrinology markers).

Standard Dosing

• Under 75 kg
  • Dose: 0.10 mL SC daily (≈ 400 mcg)
  • Schedule: 5 days on / 2 days off each week (e.g. Monday–Friday on, weekend off)

• Over 75 kg
  • Dose: 0.15 mL SC daily (≈ 600 mcg)
  • Schedule: 5 days on / 2 days off

Second Order / Follow-Up Phase

For clients who:

• Have completed an initial course,
• Have no adverse effects, and
• Have repeat pathology completed and reviewed (IGF-1, lipids, endocrine review),the clinician may consider a stepped increase:

Dose: 0.25 mL SC daily (≈ 1000 mcg)

Schedule: 5 days on / 2 days off

Timing:

Once daily, at approximately the same time each day, often in the evening or pre-bed to align with natural GH pulses, unless your clinician prefers a different time for metabolic or adherence reasons.

Route:

Subcutaneous injection into fatty tissue (e.g. lower abdomen or outer thigh) using an insulin syringe.

Technique:

• Rotate injection sites, use clean technique, and follow nurse/clinician training on self-injection.
• Do not change dose, frequency or schedule without speaking to your prescribing clinician.

Side Effects, Reactions & Medical Contraindications

Use is generally not recommended in:

• Known allergy or hypersensitivity to Tesamorelin or any component of the formulation
• Active malignancy or history of cancer unless cleared and closely monitored by an appropriate specialist (due to GH/IGF-1–related growth pathways)
• Uncontrolled diabetes, significant insulin resistance or unstable cardiovascular disease without specialist supervision
• Significant, untreated dyslipidaemia or endocrine disorders highlighted on pre-pathology work-up
• Pregnant or breastfeeding individuals (Tesamorelin is not indicated and not studied for these groups)
• Known pituitary tumours or other serious pituitary pathology unless under the direct care of an endocrinologist
• A full medical, endocrine and cardiometabolic history plus detailed baseline labs must be reviewed before Tesamorelin is prescribed.

Common Side Effects and Adverse Reactions

• Reported side effects (in clinical and trial settings) are often dose-related and may include:
• Injection-site reactions such as redness, itching, swelling, tenderness or bruising
• Joint stiffness or pain, muscle aches or mild oedema (fluid retention)
• Nausea, abdominal discomfort or digestive upset
• Headache or fatigue, particularly early in treatment or after dose increases
• Changes in blood sugar or lipids, which is why regular pathology and monitoring are essential
• Many of these are manageable with dose adjustments or timing changes, but any persistent, uncomfortable or worrying symptoms should be discussed promptly with the prescribing clinician.

Reactions Requiring Medical Attention

• Stop injections and seek medical care (or emergency services if severe) if you experience:
• Signs of a serious allergic reaction: widespread rash or hives, swelling of the face, lips or tongue, difficulty breathing or swallowing
• Severe or persistent headache, visual changes, chest pain, marked shortness of breath or palpitations
• Significant swelling of ankles/hands, rapid unexplained weight gain or dramatic changes in blood pressure
• Worsening blood-sugar control (especially in people at risk for diabetes) or other lab changes flagged as high risk by your clinician
• Any new or rapidly worsening symptom that feels serious, unusual or concerning

Safety Note

Tesamorelin is a powerful, prescription-only GHRH analogue with an established role in specific medical settings and emerging use in advanced metabolic and longevity programs. Because it directly modulates the growth hormone axis and affects visceral fat and metabolic markers, it must:

• Only be used under experienced medical supervision
• Always include baseline and follow-up pathology, with clear stop/go rules and dose-adjustment criteria
• Be understood as one part of a cardiometabolic or healthy-ageing plan, not a stand-alone solution
• Clients should be fully informed about what Tesamorelin can and cannot do, potential risks, the importance of lifestyle foundations, and the need for regular review. Informed consent, including acknowledgement of off-label use where applicable, is essential.

Safety Note: Long‑term data is limited. Use should always be monitored by a qualified clinician, with regular reviews and ongoing medical supervision.  Informed consent is essential.